Celldex Therapeutics (CLDX) is a clinical stage biotechnology company that is developing therapies for types of inflammatory, autoimmune and cancer-related diseases.
Let's check out the charts.
In this daily bar chart of CLDX, below, I see a strong rally from June. Prices made a low in June and did a quick retest in early July, before launching an impressive rally in which shares more than doubled. Prices trade above the rising 50-day moving average line and above the rising 200-day line. The On-Balance-Volume (OBV) line has largely moved sideways from August. The Moving Average Convergence Divergence (MACD) oscillator is bullish.
In this weekly Japanese candlestick chart of CLDX, below, I see a mixed picture. Prices are in a longer-term advance with prices trading above the rising 40-week moving average line. It is hard to see the trading volume and the weekly OBV line shows just a slight increase the past two years or so. The Moving Average Convergence Divergence (MACD) oscillator is in a bullish alignment above the zero-line.
In this daily Point and Figure chart of CLDX, below, I see an upside price target in the $57 area.
In this weekly Point and Figure chart of CLDX, below, I see a potential upside price target in the $68 area.
Bottom line strategy: Traders could probe the long side of CLDX on a dip to the $44 area risking to $41. $57 is my first price target.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
Previously know as Pinduoduo, weak consumer spending has plagued the stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.